Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.26 Bil Enterprise Value: 13.31 Bil PE Ratio: 70.58 PB Ratio: 2.82 GF Score: 62/100

Biomarin Pharmaceutical Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript

May 11, 2021 / 06:00PM GMT
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Okay. Welcome to the afternoon sessions of the Virtual Vegas BofA Global Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here at BofA. Aspen Mori from my team is with me as well. And we're thrilled to have BioMarin with us. And speaking on behalf of BioMarin, we have CEO, J.J. Bienaime; and also CFO, Brian Mueller. Welcome, guys.

Brian R. Mueller
BioMarin Pharmaceutical Inc. - Executive VP & CFO

Geoff, thanks for having us.

Jean;Jacques Bienaime
BioMarin Pharmaceutical Inc. - Chairman & CEO

Hi, Geoff.

Geoffrey Christopher Meacham;Jean;Jacques Bienaime<
BofA Securities, Research Division - Research Analyst

Rather be in actual Vegas but we'll make this work. So we'll do some questions. But J.J., you want to kick it off with just a couple of high-level takeaways, and then we can get right into it.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot